SpliSense Presents Preclinical Data for SPL23-ASO, mRNA-Altering Drug Candidate for the Treatment of Cystic Fibrosis, at the European Cystic Fibrosis Conference

SpliSense Presents Preclinical Data for SPL23-ASO, mRNA-Altering Drug Candidate for the Treatment of Cystic Fibrosis, at the European Cystic Fibrosis Conference

 

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on email
+972-52-836-77-31

© 2021 All rights Reserved. Design by SCOOP

Facebook
Twitter
Youtube
Scroll Up Skip to content